Coblopasvir hydrochloride

盐酸可洛派韦

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCoblopasvir hydrochloride
Drug Alias Name凯力唯KW-136
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitors
TargetsNonstructural protein 5A
Therapy Area/IndicationsHepatitis C, ChronicHepatitis C
Global Approved IndicationsHepatitis C
Approved Indications in ChinaHepatitis C
Original Approved Country/TerritoryMainland China
Original Approved Date2020/02/11
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Kawin Technology Share-Holding Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Kawin Technology Share-Holding Co LtdBeijing Furui Tiancheng Biological Technology Co Ltd
Inactive CompaniesKawin Technology Share-Holding Co LtdGinkgo Tree Pharmaceutical (Suzhou) Co Ltd
Active IndicationsHepatitis C, ChronicHepatitis C
Inactive IndicationsN/A

Other Information

ATC CodeJ05AP
Related LinksDrugBank